Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Issues in allogeneic HSCT: Therapeutic options for post-transplant relapse

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 24.05.19
Views: 369

Prof David Marks - University Hospital Bristol, Bristol, UK

Prof David Marks talks to ecancer at the European School of Haematology (ESH) meeting: International Conference on Acute Lymphoblastic Leukaemia about the main problems clinicians and patients face after a haematopoietic stem cell transplant (HSCT) is given and the options available to treat this.

Prof Marks reviews data about the therapeutic options available in the post-relapse setting - which includes administering a second transplant and CAR T-cell therapy.

He also describes the risk factors that are associated with an increased risk of relapse in these patients and the role of maintenance therapy to reduce this risk.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation